Table 1.

Baseline characteristics of included studies.

Study	Year	N	N	N	Interventions		Outcomes	Jadad score
		(Ver.)	(Dil.)	(Con.)	Expt.	Ctrl.
Taniyama et al. [16]	1997	20	0	20	0.5 mg verapamil (diluted in 10 mL saline) 120 mg po follow-up study	Blank	TIMI/LVEF/WMI	3
Vijayalakshmi et al. [19]	2006	49	0	50	0.5 mg verapamil	Heparinized	TIMI/MACE/TFC/WMI	3
Hendler et al. [20]	2006	10	0	10	0.5 mg verapamil	Heparinized	TIMI/LVEF	2
Chang et al. [21]	2010	29	0	35	100–400 μg verapamil	Nitroglycerin	CTFC	2
Huang et al. [22]	2012	34	34	34	200 μg verapamil (max 1 mg) 400 μg diltiazem (max 1 mg)	Nitroglycerin (max 1 mg)	TIMI/CTFC/LVEF/MACE	3
Li et al. [23]	2012	0	40	39	Diltiazem 90 mg bid/6 months	Placebo	TIMI/CTFC/LVEF/MACE	6
Ozdogru et al. [24]	2013	0	30	30	5 mg diltiazem	Nitroglycerin	CTFC/HR/BP	2
Akturk et al. [25]	2014	15	0	15	Verapamil	Placebo	CTFC/LEVF	2
Overall		157	104	233